Leuprorelin acetate blood levels and dialysance after the administration of sustained-release leuprorelin acetate in a dialysis case complicated by prostate cancer.
BACKGROUND
The objective of this study is to determine whether in a dialysis patient with prostate cancer leuprorelin acetate blood levels were abnormally high or low due to kidney failure or because of dialysis.


METHODS
Sustained-release leuprorelin acetate 3.75 mg was given every 4 weeks for prostate cancer in a 79-year-old dialysis patient. Changes in serum level of leuprorelin acetate in this patient were measured before and after dialysis.


RESULTS
Leuprorelin acetate appeared to have a dialysance close to that of vitamin B12, which has a similar molecular weight. The amount dialyzed did not exceed 8.3% of the amount released per day. Mean blood levels of leuprorelin acetate, as measured in this patient, were higher (0.64 to 1.31 ng/ml) than those in prostate cancer patients with normal kidney function (mean +/- SD, 0.24 +/- 0.12 to 0.50 +/- 0.32 ng/ml).


CONCLUSIONS
Sustained-release leuprorelin acetate can be used safely in dialysis patients with prostate cancer.
Saruki
K
K
Department of Urology, Hidaka Hospital, Takasaki, Japan.
Sekihara
T
T
Mashimo
M
M
Matsuo
H
H
Sekiguchi
H
H
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000097:blood*; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage / Q000097:blood*; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000097:blood* / Q000150:complications / Q000628:therapy
D018931:Antineoplastic Agents, Hormonal; D016729:Leuprolide